×
模态框（Modal）标题
在这里添加一些文本
Close
Close
Submit
Cancel
Confirm
×
模态框（Modal）标题
×
Welcome to China Oncology,
Fig/Tab
Adv Search
Home
Journal Information
About China Oncology
Open Access Statement
Index
Awards
Advertising Policy
Contact Us
Subscriptions
Editorial Board
Editorial Board Members
Youth Editorial Board Members
For Authors
Guide for Authors
Paper Template
Copyright
Others
For Reviewers
Guidelines for Reviewers
China Oncology Peer Review Policies
Archive
Archive
Most Read
Most Download
Ethics and Policies
Article Screening for Plagiarism Policy
Statement on the Publishing Ethics and Publication Malpractice
China Oncology Editorial Policies
Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of Concern
Research Ethics policy
Others
Email Alert
中文
Health-related quality of life study of tislelizumab versus single-agent chemotherapy in second-line treatment for advanced urothelial cancer in real-world clinical practice
BIAN xiaojie , SHEN yijun , ZHU yiping, MA chunguang, GU chengyuan, YE dingwei
China Oncology . 2020, (
10
): 798 -805 . DOI: 10.19401/j.cnki.1007-3639.2020.10.011
